Institute of Virology, Vaccines and Sera “Torlak”

What Institute of Virology, Vaccines and Sera “Torlak” does

The Institute of Virology, Vaccines and Sera "Torlak" is a state-owned public health institution headquartered in Belgrade, Serbia, established in 1924 as the Central Hygiene Institute and renamed in 1947. It operates as the sole domestic manufacturer of vaccines and bacterial sera in Serbia, producing human vaccines (notably the seasonal influenza vaccine TorVaxFlu, for which it holds GMP certification), bacterial sera, and diagnostic reagents, while also providing vaccine distribution, microbiological and immunoserological diagnostics, and consulting services across the region. The institute hosts four national reference laboratories designated by the World Health Organization — for influenza and respiratory viruses, poliomyelitis, measles/rubella, and rotavirus — alongside dedicated centers for serology, tissue typing, biomonitoring, and parasitology.

Torlak's underlying technology stack rests on classical biopharmaceutical platforms (egg- and cell-based vaccine production, fermentation, ELISA, PCR, flow cytometry) supported by ISO 9001, ISO 14001, ISO 45001, and GMP certifications, with WHO-UNICEF supply compliance. It is currently extending this base through an mRNA technology transfer partnership coordinated by the World Health Organization, the Medicines Patent Pool, CEPI, and BARDA, and is constructing a BSL-3 containment laboratory funded under the broader SAIGE (Serbia Accelerating Innovation and Growth Project) initiative backed by the World Bank.

The business model is government-financed and procurement-driven. Revenue derives primarily from sale of vaccines, sera, and diagnostic products to Serbia's national health insurance fund (RFZO) and Ministry of Health, supplemented by tender-based exports, contract research services, and reference-laboratory testing. There are no private equity investors, subsidiaries, or disclosed financial statements; the institute functions as a strategic state asset rather than a commercial enterprise.

Name

Institute of Virology, Vaccines and Sera “Torlak”

Legal name

Institute of Virology, Vaccines and Sera "Torlak" (Institut za virusologiju, vakcine i serume "Torlak")

Website

https://torlak.rs

Company type

Private

Founded year

1924

Operating status

Operating

Headcount range

51–100 employees

Short description

State-owned Serbian public health institute (founded 1924) that manufactures vaccines and bacterial sera, hosts four WHO national reference laboratories, and provides microbiological diagnostics and consulting services primarily to the Serbian government.

Ownership category

akta.pro rank

Product category

Vaccine and Biological Products Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK), Vaccine Quality, Safety & Pharmacovigilance (HLAIAEAL), Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM), Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

Keywords

• Vaccine manufacturing
• Diagnostic laboratory services
• Biological products
• National reference laboratory
• Immunobiological preparations

Headquarters

HQ city

Belgrade

HQ country

Serbia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Vaccine and biological product sales: Production and sale of vaccines (influenza, BCG, diphtheria, tetanus, pertussis historically), serums, allergens, and immunobiological preparations to healthcare institutions nationwide. Products supplied to healthcare institutions on the territory of Republic of Serbia.
2. Diagnostic laboratory services: Comprehensive diagnostic testing including serological, molecular (PCR), bacteriological, and immunological-allergological diagnostics. Services available both covered by national health insurance (RFZO) and as commercial self-pay services.
3. Microbiological culture media and reagents: Production and sale of dry and ready-to-use microbiological culture media, diagnostic reagents, virological transport medium, cell culture media, and water for pharmaceutical use.
4. Trade operations: Import and export of medicines, medical devices, dietary products, and raw materials for pharmaceutical production.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

The Institute of Virology, Vaccines and Sera "Torlak" is Serbia's national state-owned manufacturer of vaccines (BCG, TorVaxFlu influenza, diphtheria, tetanus, pertussis, OPV), therapeutic sera (antivenom), allergens, PPD-tuberculin, lactopreparations, and microbiological culture media, supplying public and private healthcare institutions across Serbia. It also operates a comprehensive diagnostic laboratory providing serological, molecular (RT-PCR), allergological, autoimmune, bacteriological, and immunological infertility testing, alongside four WHO-designated national reference laboratories for influenza, poliomyelitis, measles/rubella, and arboviruses.

Product overview

The Institute of Virology, Vaccines and Sera "Torlak" is a comprehensive pharmaceutical and diagnostic institution offering a broad portfolio of products and services. Its product portfolio includes bacterial and viral vaccines (BCG, influenza vaccine TorVaxFlu, diphtheria, tetanus, pertussis, and oral polio vaccines), therapeutic sera (antivenom sera), immunodiagnostics (allergens, PPD-tuberculin), lactopreparations, and microbiological culture media (dry media, ready-to-use media, virological transport medium, cell culture media). The diagnostic services include serological testing (ELISA, Western Blot), molecular diagnostics via RT-PCR, allergy testing, autoimmune disease diagnostics, and bacteriological diagnostics including custom autovaccines. As a national reference laboratory for multiple viral diseases designated by WHO, Torlak also conducts fundamental and applied research in immunology, molecular biology, and biochemistry, with active mRNA vaccine technology development. The institution operates under GMP standards and maintains multiple ISO certifications.

Differentiator

Problem solved

Functional benefit

Brands

• TorVaxFlu: Split, inactivated influenza vaccine produced by the Institute

Products and services

• TorVaxFlu (Split Inactivated Influenza Vaccine) Split, inactivated influenza vaccine produced domestically since 2015 with GMP certification, for use in national immunization programs and supply to healthcare institutions in Serbia.
• BCG Vaccine Bacillus Calmette-Guérin vaccine for tuberculosis prevention, one of the Institute's longest-produced biological products.
• Diphtheria Vaccine and Anti-Diphtheria Serum Vaccine according to Ramon method and therapeutic serum for prevention and treatment of diphtheria.
• Tetanus Vaccine Tetanus vaccine produced according to the Ramon method for national immunization.
• Pertussis Vaccine Whooping cough vaccine produced from domestic bacterial isolates.
• OPV (Oral Polio Vaccine) Live oral polio vaccine against childhood paralysis, produced from original Sabin strains.
• Antivenom Sera Therapeutic sera for venom neutralization.
• PPD-Tuberculin Tuberculin purified protein derivative for tuberculosis skin testing.
• Allergens and Allergen-Specific Immunotherapy Allergen preparations for diagnostic skin prick testing and targeted allergen-specific immunotherapy that modifies the course of allergic disease.
• Autovaccines Custom bacterial vaccines prepared from patient-specific isolates for chronic urogenital, respiratory, wound, skin, eye, nose, and ear infections.
• Dry Bacteriological Media Powdered microbiological culture media for diagnostic microbiology with CE marking per ISO 13485.
• Ready-to-Use Microbiological Media Pre-prepared culture media for immediate microbiological use in clinical and food-safety laboratories.
• Virological Transport Medium Medium for safe transport and preservation of viral specimens, CE-marked under ISO 13485.
• Cell Culture Media Specialized media for maintaining and growing cell cultures used in virological and biological research and production.
• Water for Pharmaceutical Use Purified water meeting pharmaceutical quality standards for production and laboratory use.
• Serological Diagnostic Services Detection of antibodies and antigens for viral, bacterial, and parasitic infections using ELISA, Western Blot, and neutralization tests, available via RFZO referral and self-pay.
• Molecular Diagnostics (RT-PCR) Real-time PCR testing for viral and bacterial pathogen genome detection including influenza subtypes, SARS-CoV-2, Mpox, HPV, Borrelia, and panels.
• Allergy Diagnostic Services (Prick Tests) Skin prick testing for inhalant and food allergens including dog/cat dander, dust mites, pollens, eggs, milk, and other common allergens.
• Autoimmune Disease Diagnostics Testing for autoimmune markers including anti-phospholipid syndrome, celiac disease, Crohn's disease, SLE, vasculitis, and Sjögren's syndrome using the EliA platform.
• Immunological Infertility Testing Evaluation of immunological causes of infertility including antisperm antibodies and sperm DNA fragmentation analysis (spermogram).
• Bacteriological Diagnostic Services Standard bacteriological testing including culture, identification, and autovaccine production for chronic bacterial infections.
• National Reference Laboratory for Influenza and Other Respiratory Viruses WHO-designated national reference laboratory for influenza surveillance in Serbia.
• National Reference Laboratory for Poliomyelitis and Enterovirus National reference laboratory for poliomyelitis and enterovirus surveillance in Serbia.
• National Reference Laboratory for Measles, Rubella, Varicella, and Other Rashes National reference laboratory for measles, rubella, varicella, and other rash-causing viral disease surveillance.
• National Reference Laboratory for Arboviruses and Hemorrhagic Fevers National reference laboratory for arbovirus and hemorrhagic fever surveillance in Serbia.

Quantifiable outcome

• First SARS-CoV-2 case in Serbia diagnosed at Torlak Institute on March 6, 2020

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered core, major and minor.

• World Health Organisation (WHO)coreStrategic or Co-development PartnerWHO collaboration including mRNA technology transfer project, office head Dr. Fabio Scano visit in May 2024. Partnership庆祝 for technology transfer implementation with Medicines Patent Pool.
• Medicines Patent Pool (MPP)coreStrategic or Co-development PartnerPartnership with WHO for mRNA technology transfer project to enable production of vaccines and biologics in Serbia.
• Coalition for Epidemic Preparedness Innovations (CEPI)coreStrategic or Co-development PartnerInternational partnership for epidemic preparedness and vaccine development support.
• Biomedical Advanced Research and Development Authority (BARDA)coreStrategic or Co-development PartnerUS government agency supporting advanced research and development of medical countermeasures, partnership in vaccine technology development.
• Afrigen Biologics and VaccinescoreStrategic or Co-development PartnerSouth African company involved in mRNA technology transfer hub network supporting vaccine production capabilities.
• Developing Countries Vaccine Manufacturing Network (DCVMN)coreStrategic or Co-development PartnerGlobal network of vaccine manufacturers from developing countries, providing collaboration and technology sharing opportunities.
• Government of Republic of SerbiacoreOthersFounder and primary supporter of Torlak Institute. Provides funding for infrastructure projects including BSL-3 laboratory construction. Appointed supervisory and managing boards.
• Ministry of Health of the Republic of SerbiacoreOthersPrimary regulatory and oversight authority. Approved current name in April 2008. Institute operates under its jurisdiction.
• Ministry of Science, Technological Development and InnovationcoreOthersGovernment ministry providing oversight and funding for scientific research activities at the Institute.
• Centers for Disease Control and Prevention (CDC)majorStrategic or Co-development PartnerUS public health agency partnership for disease surveillance and control support.
• European Centre for Disease Prevention and Control (ECDC)majorStrategic or Co-development PartnerEU agency partnership for infectious disease surveillance and prevention.
• Program for Appropriate Technology in Health (PATH)minorStrategic or Co-development PartnerInternational nonprofit organization for appropriate technology in health.
• Charles River LaboratoriesmajorStrategic or Co-development PartnerWorkshop on laboratory animals hosted by Torlak in March 2024 with Dr. Aleksandar Popovic from UK office. Supported by SAIGE project.
• Faculty of Medicine, University of BelgrademajorStrategic or Co-development PartnerDomestic academic partner. Managing Board President Prof. Dr. Dusan Popadic from Faculty of Medicine.
• SAIGE Project (Serbia Accelerating Innovation and Entrepreneurship)coreStrategic or Co-development PartnerWorld Bank-supported project for innovation acceleration and entrepreneurship growth. Supporting Institute transformation and BSL-3 laboratory construction.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Bio-Manguinhos (Fiocruz): Brazilian federal vaccine and diagnostics manufacturer affiliated with Fiocruz. Comparable state-owned producer of vaccines, diagnostics, and reference biologicals for national immunization program.
• Gamaleya Research Institute: Russian state-owned research institute producing vaccines (including Sputnik) and immunobiologicals. Comparable as a government-backed vaccine manufacturer with national reference and pandemic preparedness role.
• Butantan Institute: Brazilian state-owned vaccine and serum producer with national reference laboratory functions, supplying public health system under government mandate. Comparable as a state-backed national biologics manufacturer with diversified portfolio.
• Institut Pasteur: Historic French research institute founded 1887 with vaccine R&D, diagnostic services, and reference laboratory functions. Closest comparable in mission, structure, and product breadth (vaccines + diagnostics + reference labs).

Emerging players

• Bavarian Nordic: Danish commercial vaccine manufacturer specializing in smallpox/monkeypox, rabies, and travel vaccines. Comparable in niche vaccine development and contract manufacturing with government/public-sector customers.
• Afrigen Biologics and Vaccines: South African biotech and WHO mRNA technology transfer hub partner. Direct comparable as a co-participant in the WHO/MPP mRNA hub-and-spoke program Torlak is also part of.
• Serum Institute of India: World's largest vaccine manufacturer by doses; private-sector scale producer of traditional and newer vaccines. Comparable in established-vaccine product lines (BCG, DTP, OPV) but at vastly greater commercial scale.

Broad incumbents

• Sanofi Pasteur: Global vaccines business unit of Sanofi, one of the largest vaccine manufacturers worldwide. Comparable in product lines (influenza, polio, BCG/DTP) but operates at global commercial scale rather than national level.
• China National Biotec Group (CNBG/Sinopharm): State-owned Chinese vaccine and biological products conglomerate producing a broad portfolio including COVID-19, polio, and influenza vaccines. Comparable as a state-backed, national-level biologics manufacturer.
• GSK Vaccines: Major global vaccine manufacturer with broad portfolio including influenza, polio, and combination vaccines. Listed as a partner on Torlak's website; comparable in traditional vaccine product overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/institute-of-virology-vaccines-and-sera-%E2%80%9Ctorlak%E2%80%9D

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute of Virology, Vaccines and Sera “Torlak”